Is Mirati Therapeutics Inc (MRTX) Stock a Smart Investment Wednesday?
Wednesday, January 19, 2022 03:13 PM | InvestorsObserver Analysts
Mentioned in this article
Mirati Therapeutics Inc (MRTX) stock is lower by -43.43% over the last 12 months, and the average rating from Wall Street analysts is a Buy. InvestorsObserver’s proprietary ranking system, gives MRTX stock a score of 25 out of a possible 100.
That rank is primarily influenced by a short-term technical score of 2. MRTX's rank also includes a long-term technical score of 15. The fundamental score for MRTX is 59. In addition to the average rating from Wall Street analysts, MRTX stock has a mean target price of $195.75. This means analysts expect the stock to climb 59.95% over the next 12 months.
MRTX has an Overall Score of 25. Find out what this means to you and get the rest of the rankings on MRTX!
Mirati Therapeutics Inc (MRTX) stock is higher by 5.52% while the S&P 500 is lower by -0.08% as of 3:12 PM on Wednesday, Jan 19. MRTX has risen $6.40 from the previous closing price of $115.98 on volume of 454,701 shares. Over the past year the S&P 500 has gained 20.39% while MRTX is lower by -43.43%. MRTX lost -$9.53 per share in the over the last 12 months.
Click Here to get the full Stock Report for Mirati Therapeutics Inc stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
